

Mini-Hyper CVD+CRIB (Condensed Rituximab, Inotuzumab Ozogamicin, and Blinatumomab) for Refractory Pediatric B-ALL

David McCall¹, Elias Jabbour², Michael Roth¹, Cesar Nunez¹, and Branko Cuglievan¹

¹Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas

²The University of Texas MD Anderson Cancer Center Department of Leukemia

June 16, 2022

Abstract

Relapsed or refractory pediatric B-Acute Lymphoblastic Leukemia (B-ALL) patients have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5-year-old male with high-risk B-ALL that was refractory to several re-induction regimens. He was put into MRD-negative remission after re-induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin and blinatumomab, termed Mini-Hyper-CVD plus CRIB. This was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use in pediatrics of a condensed sequential immunotherapy/chemotherapy regimen in a pediatric leukemia patient.

Hosted file

miniCVD_PBC_Brief Report.docx available at <https://authorea.com/users/436622/articles/573242-mini-hyper-cvd-crib-condensed-rituximab-inotuzumab-ozogamicin-and-blinatumomab-for-refractory-pediatric-b-all>